ArticleBBA advances2026
AGTRAP mediates exosome-driven communication between cancer cells and macrophages via p38 MAPK pathway to promote hepatocellular carcinoma.
Article in BBA advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angiotensin II Receptor-Associated Protein (AGTRAP) is markedly overexpressed in hepatocellular carcinoma (HCC) cases associated with poor prognosis; however, its precise functional role remains inadequately elucidated. Objective: This study aimed to elucidate the functional role of AGTRAP in HCC progression and its impact on the tumor microenvironment (TME). Methods: We knocked down AGTRAP expression in HCC cell lines (HepG2 and SK-hep1) using shRNA and evaluated the impact of AGTRAP knockdown on hepatocellular carcinoma cells through proliferation, invasion, and migration. Immunofluorescence staining was used to analyze the distribution of M1-type and M2-type macrophages in HCC patient tissues. The signaling pathway mechanism by which AGTRAP regulates macrophage polarization was further analyzed, focusing on the p38 MAPK pathway. The effects and mechanisms of exosomes derived from AGTRAP-knockdown HCC cells on macrophage polarization were investigated. Results: Silencing AGTRAP significantly enhanced apoptosis, disrupted cell cycle progression, and diminished the invasive and migratory capacities of HCC cells.Tumors with high AGTRAP expression exhibited increased M2-type macrophages and decreased M1-type macrophages, indicating a shift in the TME towards an immunosuppressive state.Mechanistic studies revealed that AGTRAP modulates macrophage polarization by interacting with the p38 MAPK signaling pathway.Exosomes derived from AGTRAP-silenced HCC cells also influenced macrophage polarization via the p38 MAPK pathway. Conclusion: AGTRAP facilitates HCC progression by mediating exosomal communication between cancer cells and macrophages via the p38 MAPK pathway, underscoring its pivotal role in shaping the immunosuppressive tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.